Efficacy of 42-month oral administration of glucoraphanin in preventing cognitive decline in individuals at elevated risk of dementia, including those with mild cognitive impairment: a randomized, double-blind, placebo-controlled pilot study.

However, the effect of GLR became more pronounced over time, with a trend toward significance at 18 months (Std. β [95% CI] = 0.57 [−0.00; 1.15], p = 0.071) and significant group by time-point interactions emerging at 30 months (Std. β [95% CI] = 0.84 [0.24; 1.45], p = 0.012) and 42 months (Std. β [95% CI] = 0.71 [0.09; 1.33], p = 0.036, Supplementary Table 1 ).

also in 3,729 other papers

Specifically, the 42-month endpoint, the change in MPI score from baseline tended to be greater in the GLR group than in the placebo group; however, this difference did not reach statistical significance (Median [IQR] = 3.6 [2.3; 11.8] for the placebo group vs. 13.4 [8.4; 19.9] for GLR group. p = 0.079, PPS analysis, Table 3 ).

also in 111,027 other papers

At the endpoint (42-month), only a significant trend in MPI score was observed, and a larger sample size is required to obtain robust results demonstrating the effect on MPI score.

also in 9,775 other papers